Satellos Bioscience (MSLE) Invested Capital (2024 - 2025)
Satellos Bioscience's (MSLE) quarterly Invested Capital came in at $2.3 million in Q4 2025, up 48.75% year-on-year from $1.5 million in Q4 2024, and up 48.75% on a QoQ basis from $1.5 million in Q4 2024.
Satellos Bioscience (MSLE) Invested Capital (2024 - 2025) Analysis & Trends
Satellos Bioscience (MSLE) has 2 years of Invested Capital data on file, last reported at $2.3 million in Q4 2025.
- On a quarterly basis, Invested Capital rose 48.75% year-over-year to $2.3 million in Q4 2025; TTM through Mar 2026 was $3.8 million, a N/A change from a year earlier, with the FY2025 full-year figure at $2.3 million, changed N/A from the prior year.
- Invested Capital for Q4 2025 stood at $2.3 million, up from $1.5 million in the prior quarter.
- Over the last five years, Invested Capital for MSLE reached as high as $2.3 million in Q4 2025 and fell as low as $1.5 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Invested Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | - |
| 2 | Nanobiotix | 1,913.50 Bn | 1,913.44 Bn | - | 110.96 Mn |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 473.74 Bn | 468.95 Bn | 1.35 Bn | 116.14 Mn |
| 5 | Vertex Pharmaceuticals | 122.07 Bn | 114.82 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.00 Bn | 61.24 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.96 Bn | 50.77 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | - |
| 10 | Satellos Bioscience | 175.96 Mn | 175.96 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.26 Mn |
| Dec 31, 2024 | 1.52 Mn |